BlackRock, Inc. 13D and 13G filings for Cytokinetics, Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 11:44 am Unchanged |
2024-09-30 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
15,252,905 13.000% |
0 (Unchanged) |
Filing |
| 2024-10-23 5:04 pm Sale |
2024-09-30 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
15,252,905 13.000% |
-1,047,636 (-6.43%) |
Filing |
| 2024-01-22 2:03 pm Purchase |
2023-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
16,300,541 16.400% |
532,667 (+3.38%) |
Filing |
| 2023-02-10 2:11 pm Unchanged |
2022-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
15,767,874 16.700% |
0 (Unchanged) |
Filing |
| 2023-01-26 08:52 am Purchase |
2022-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
15,767,874 16.000% |
800,557 (+5.35%) |
Filing |
| 2023-01-20 3:00 pm Purchase |
2022-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
14,967,317 16.000% |
2,016,353 (+15.57%) |
Filing |
| 2022-01-27 1:59 pm Unchanged |
2021-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
12,950,964 15.400% |
0 (Unchanged) |
Filing |
| 2022-01-25 6:45 pm Purchase |
2021-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
12,950,964 15.400% |
1,339,885 (+11.54%) |
Filing |
| 2021-01-25 4:50 pm Purchase |
2020-12-31 | 13G | Cytokinetics, Incorporated CYTK |
BlackRock Inc. BLK |
11,611,079 16.400% |
2,050,477 (+21.45%) |
Filing |